Abstract
The aim of the current investigation was to develop a Sustained release tablet of Donepezil Hydrochloride using non- gelling polymer in order to overcome the problem of dose dumping. Viscarin GP-209 was used as a non-gelling release modifying agent. The formulated granule blends were evaluated for powder properties. Prepared tablets were subjected to post compression evaluations. In-vitro dissolution studies were carried out in 3 different dissolution profiles. Profile1: 0.1 N Hcl medium, Profile 2: pH 5.5 sodium phosphate buffer medium and Profile3: in 0.1 N Hcl for 2hrs and in 6.8 pH sodium phosphate buffer medium using the USP Type 2 apparatus as per the FDA guidelines. The dissolution data was fitted into various kinetic models to determine the release mechanism and mean dissolution time. Formulation F6 was considered as optimized as it showed similar drug release pattern with that of innovator immediate release formulation and similarity factor (f2) of 82. F6 formulation was found to be stable up to 3 months of stability testing at 40 o c / 75%RH.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.